Progression to study outcomes dependent on fibrinogen and Fibtem at study entry
| . | Clauss fibrinogen (g/L) . | Fibtem A5 (mm) . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | <2 (n = 12) . | 2-2.9 (n = 65) . | 3-3.9 (n = 117) . | ≥4 (n = 147) . | <10 (n = 14) . | 10-15 (n = 62) . | 16-22 (n = 161) . | ≥23 (n = 89) . |
| Total bleed volume (mL), median (25th-75th centiles) | 2430 (1600-3500) | 1500 (1200-2000) | 1500 (1200-2000) | 1400 (1200-1650) | 2980 (1875-3875) | 1650 (1200-2100) | 1435 (1200-1950) | 1300 (1100-1563) |
| Bleed >2500 mL, n (%) | 6 (50) | 12 (19) | 8 (6.9) | 9 (6.4) | 8 (57) | 12 (20) | 10 (6.3) | 3 (4.3) |
| Women receiving RBCs, n (%) | 9 (75) | 35 (54) | 30 (26) | 30 (20) | 10 (71) | 27 (44) | 39 (24) | 19 (21) |
| RBC units transfused, median (25th-75th centiles) | 4 (2.25-5.25) | 1 (0-2) | 0 (0-1) | 0 (0-0) | 3.5 (0.5-7.25) | 0 (0-2) | 0 (0-0) | 0 (0-0) |
| Women receiving ≥4 U RBCs, n (%) | 8 (67) | 11 (17) | 6 (5.1) | 6 (4.1) | 7 (50) | 12 (19) | 7 (4.3) | 2 (2.2) |
| Women receiving FFP, n (%) | 9 (75) | 15 (23) | 8 (6.8) | 6 (4.1) | 8 (57) | 15 (24) | 11 (6.8) | 2 (2.2) |
| Women receiving ≥8 U blood products, n (%) | 9 (75) | 8 (12) | 4 (3.4) | 4 (2.7) | 8 (57) | 8 (13) | 5 (3.1) | 2 (2.2) |
| Platelet transfusion, n (%) | 5 (42) | 2 (3.1) | 2 (1.7) | 2 (1.4) | 4 (29) | 2 (3.2) | 2 (1.2) | 1 (1.1) |
| Fibrinogen concentrate, n (%) | 5 (42) | 3 (4.6) | 0 (0) | 0 (0) | 4 (29) | 3 (4.8) | 0 (0) | 0 (0) |
| Women receiving invasive procedures, n (%) | 5 (42) | 4 (6.2) | 5 (4.3) | 2 (1.4) | 4 (29) | 4 (6.5) | 3 (1.9) | 4 (4.5) |
| . | Clauss fibrinogen (g/L) . | Fibtem A5 (mm) . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | <2 (n = 12) . | 2-2.9 (n = 65) . | 3-3.9 (n = 117) . | ≥4 (n = 147) . | <10 (n = 14) . | 10-15 (n = 62) . | 16-22 (n = 161) . | ≥23 (n = 89) . |
| Total bleed volume (mL), median (25th-75th centiles) | 2430 (1600-3500) | 1500 (1200-2000) | 1500 (1200-2000) | 1400 (1200-1650) | 2980 (1875-3875) | 1650 (1200-2100) | 1435 (1200-1950) | 1300 (1100-1563) |
| Bleed >2500 mL, n (%) | 6 (50) | 12 (19) | 8 (6.9) | 9 (6.4) | 8 (57) | 12 (20) | 10 (6.3) | 3 (4.3) |
| Women receiving RBCs, n (%) | 9 (75) | 35 (54) | 30 (26) | 30 (20) | 10 (71) | 27 (44) | 39 (24) | 19 (21) |
| RBC units transfused, median (25th-75th centiles) | 4 (2.25-5.25) | 1 (0-2) | 0 (0-1) | 0 (0-0) | 3.5 (0.5-7.25) | 0 (0-2) | 0 (0-0) | 0 (0-0) |
| Women receiving ≥4 U RBCs, n (%) | 8 (67) | 11 (17) | 6 (5.1) | 6 (4.1) | 7 (50) | 12 (19) | 7 (4.3) | 2 (2.2) |
| Women receiving FFP, n (%) | 9 (75) | 15 (23) | 8 (6.8) | 6 (4.1) | 8 (57) | 15 (24) | 11 (6.8) | 2 (2.2) |
| Women receiving ≥8 U blood products, n (%) | 9 (75) | 8 (12) | 4 (3.4) | 4 (2.7) | 8 (57) | 8 (13) | 5 (3.1) | 2 (2.2) |
| Platelet transfusion, n (%) | 5 (42) | 2 (3.1) | 2 (1.7) | 2 (1.4) | 4 (29) | 2 (3.2) | 2 (1.2) | 1 (1.1) |
| Fibrinogen concentrate, n (%) | 5 (42) | 3 (4.6) | 0 (0) | 0 (0) | 4 (29) | 3 (4.8) | 0 (0) | 0 (0) |
| Women receiving invasive procedures, n (%) | 5 (42) | 4 (6.2) | 5 (4.3) | 2 (1.4) | 4 (29) | 4 (6.5) | 3 (1.9) | 4 (4.5) |